Tags

Type your tag names separated by a space and hit enter

Decoy receptor 3 levels in peripheral blood predict outcomes of acute respiratory distress syndrome.
Am J Respir Crit Care Med. 2009 Oct 15; 180(8):751-60.AJ

Abstract

RATIONALE

Acute respiratory distress syndrome (ARDS), a serious inflammatory reaction to acute lung injury, is associated with high mortality rates. Decoy receptor (DcR) 3 is a soluble protein with immunomodulatory effects. Biomarkers that reliably predict outcomes in ARDS are not currently available.

OBJECTIVES

Comparing DcR3 with the Acute Physiology and Chronic Health Evaluation (APACHE) II scores and three other plasma markers to explore the association of DcR3 and the clinical outcome in ARDS.

METHODS

Eighty-eight patients with ARDS were studied. Baseline APACHE II scores and clinical data were recorded. Plasma levels of DcR3, soluble triggering receptor expressed on myeloid cells (sTREM)-1, tumor necrosis factor (TNF)-alpha, and IL-6 were measured on Day 1 and later time points, and correlated with the survival status on Day 28 after the onset of ARDS. For validation, 59 patients with ARDS from another medical center were studied.

MEASUREMENTS AND MAIN RESULTS

Among the biomarkers evaluated, only DcR3 discriminated the survivors and nonsurvivors at all time points in the first week of ARDS. DcR3 independently associated with and best predicted the 28-day mortality of patients with ARDS. Plasma DcR3 levels most correlated to multiple-organ dysfunction and ventilator dependence. Compared with survivors, the nonsurvivors had higher DcR3 levels regardless of the APACHE II scores. Kaplan-Meier survival analysis showed higher mortality in patients with ARDS with higher DcR3 levels. The outcome prediction of patients with ARDS by plasma DcR3 levels was recapitulated by the validation cohort.

CONCLUSIONS

High plasma DcR3 levels correlate with development of multiple-organ dysfunction and independently predict the 28-day mortality in patients with ARDS.

Authors+Show Affiliations

Institute of Clinical Medicine, National Yang-Ming University, Taipei.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19644047

Citation

Chen, Cheng-Yu, et al. "Decoy Receptor 3 Levels in Peripheral Blood Predict Outcomes of Acute Respiratory Distress Syndrome." American Journal of Respiratory and Critical Care Medicine, vol. 180, no. 8, 2009, pp. 751-60.
Chen CY, Yang KY, Chen MY, et al. Decoy receptor 3 levels in peripheral blood predict outcomes of acute respiratory distress syndrome. Am J Respir Crit Care Med. 2009;180(8):751-60.
Chen, C. Y., Yang, K. Y., Chen, M. Y., Chen, H. Y., Lin, M. T., Lee, Y. C., Perng, R. P., Hsieh, S. L., Yang, P. C., & Chou, T. Y. (2009). Decoy receptor 3 levels in peripheral blood predict outcomes of acute respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine, 180(8), 751-60. https://doi.org/10.1164/rccm.200902-0222OC
Chen CY, et al. Decoy Receptor 3 Levels in Peripheral Blood Predict Outcomes of Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med. 2009 Oct 15;180(8):751-60. PubMed PMID: 19644047.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Decoy receptor 3 levels in peripheral blood predict outcomes of acute respiratory distress syndrome. AU - Chen,Cheng-Yu, AU - Yang,Kuang-Yao, AU - Chen,Mei-Yu, AU - Chen,Hsuan-Yu, AU - Lin,Ming-Tzer, AU - Lee,Yu-Chin, AU - Perng,Reury-Perng, AU - Hsieh,Shie-Liang, AU - Yang,Pan-Chyr, AU - Chou,Teh-Ying, Y1 - 2009/07/30/ PY - 2009/8/1/entrez PY - 2009/8/1/pubmed PY - 2009/11/3/medline SP - 751 EP - 60 JF - American journal of respiratory and critical care medicine JO - Am J Respir Crit Care Med VL - 180 IS - 8 N2 - RATIONALE: Acute respiratory distress syndrome (ARDS), a serious inflammatory reaction to acute lung injury, is associated with high mortality rates. Decoy receptor (DcR) 3 is a soluble protein with immunomodulatory effects. Biomarkers that reliably predict outcomes in ARDS are not currently available. OBJECTIVES: Comparing DcR3 with the Acute Physiology and Chronic Health Evaluation (APACHE) II scores and three other plasma markers to explore the association of DcR3 and the clinical outcome in ARDS. METHODS: Eighty-eight patients with ARDS were studied. Baseline APACHE II scores and clinical data were recorded. Plasma levels of DcR3, soluble triggering receptor expressed on myeloid cells (sTREM)-1, tumor necrosis factor (TNF)-alpha, and IL-6 were measured on Day 1 and later time points, and correlated with the survival status on Day 28 after the onset of ARDS. For validation, 59 patients with ARDS from another medical center were studied. MEASUREMENTS AND MAIN RESULTS: Among the biomarkers evaluated, only DcR3 discriminated the survivors and nonsurvivors at all time points in the first week of ARDS. DcR3 independently associated with and best predicted the 28-day mortality of patients with ARDS. Plasma DcR3 levels most correlated to multiple-organ dysfunction and ventilator dependence. Compared with survivors, the nonsurvivors had higher DcR3 levels regardless of the APACHE II scores. Kaplan-Meier survival analysis showed higher mortality in patients with ARDS with higher DcR3 levels. The outcome prediction of patients with ARDS by plasma DcR3 levels was recapitulated by the validation cohort. CONCLUSIONS: High plasma DcR3 levels correlate with development of multiple-organ dysfunction and independently predict the 28-day mortality in patients with ARDS. SN - 1535-4970 UR - https://www.unboundmedicine.com/medline/citation/19644047/Decoy_receptor_3_levels_in_peripheral_blood_predict_outcomes_of_acute_respiratory_distress_syndrome_ L2 - https://www.atsjournals.org/doi/10.1164/rccm.200902-0222OC?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -